

Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioural, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 2

Garth L. Nicolson and Jörg Haier

ABSTRACT

Chronically ill patients with neurodegenerative and neurobehavioural and psychiatric diseases commonly have systemic and central nervous system bacterial and viral infections. In addition, other chronic illnesses where neurological manifestations are routinely found, such as fatiguing and autoimmune diseases, Lyme disease and Gulf War illnesses, also show systemic bacterial and viral infections that could be important in disease inception, progression or increasing the types/severities of signs and symptoms. Evidence of *Mycoplasma* species, *Chlamydia pneumoniae*, *Borrelia burgdorferi*, human herpesvirus-1, -6 and -7 and other bacterial and viral infections revealed high infection rates in the above illnesses that were not found in controls. Although the specific roles of chronic infections in various diseases and their pathogenesis have not been carefully determined, the data suggest that chronic bacterial and/or viral infections are common features of progressive chronic diseases.

ABBREVIATIONS

Ab Beta Amyloid; AD Alzheimer's Disease; ADHD Attention-Deficit Hyperactivity Disorder; ALS Amyotrophic Lateral Sclerosis; ASD Autism Spectrum Disorders; EBV Epstein-Barr Virus; CFS Chronic Fatigue Syndrome; CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyopathy; CI Confidence Interval; CMV Cytomegalovirus; CSF Cerebrospinal Fluid; CNS Central Nervous System; ELISA Enzyme Linked Immunoabsorbant Assay; GS Guillain-Barré Syndrome; GWI Gulf War Illnesses; HHV Human Herpes Virus; HSV Herpes Simplex Virus; MDD Major Depressive Disorder; ME Myalgic Encephalomyelitis; MRI Magnetic Resonance Imaging; MS Multiple Sclerosis; OCD Obsessive-Compulsive Disorder; PANDAS Paediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococci; PCR Polymerase Chain Reaction; PD Parkinson's Disease; QOL Quality Of Life; TS Tourette's Syndrome

Introduction

In the first part of this review we considered neurodegenerative and neurobehavioural diseases and the findings that these diseases commonly are associated with systemic and central nervous system bacterial and viral infections.¹ In this second part we continue with psychiatric diseases, autoimmune diseases, fatiguing illnesses, and other chronic diseases where chronic infections play an important role.

Psychiatric diseases

Borrelia-associated psychiatric disorders

In addition to neurologic and rheumatologic symptoms *Borrelia burgdorferi* has been associated with several psychiatric manifestations^{2, 3} (see also below). Such infections can invade the central nervous system and may cause or mimic psychiatric disorders or cause a co-morbid condition. A broad range of psychiatric conditions have been associated with Lyme disease, including paranoia, dementia, schizophrenia, bipolar disorder, panic attacks, major depression, anorexia nervosa and obsessive-compulsive disorder.⁴⁻⁷ For example, depressive states among patients with late Lyme disease are fairly common, ranging from 26% to 66%.³ It is not known whether *B. burgdorferi* contributes to overall psychiatric morbidity, but

undiagnosed chronic Lyme disease caused by this spirochete is considered a differential diagnosis in patients with certain psychiatric symptoms such as depressive symptoms, lack of concentration and fatigue.

The neuropsychiatric sequelae of chronic Lyme disease remains unclear. Studies were performed, some on large numbers of patients, to investigate whether a correlation exists between chronic Lyme disease (defined by seropositivity) and psychiatric disorders.⁸⁻¹¹ Interestingly, different results were reported on the association between *B. burgdorferi* infection and psychiatric morbidity.⁸⁻¹¹ For example, Hájek et al.⁸ compared the prevalence of antibodies to *B. burgdorferi* in groups of psychiatric patients and healthy subjects. Among the matched pairs, 33% of the psychiatric patients and 19% of the healthy comparison subjects were seropositive. In contrast, Grabe et al.¹¹ did not find an association between *Borrelia* seropositivity and mental and physical complaints. In 926 consecutive psychiatric patients that were screened for antibodies and compared with 884 simultaneously recruited healthy subjects, seropositive psychiatric patients were found to be significantly younger than seronegative ones, and this was not found in the healthy controls.¹⁰ However, none of the psychiatric diagnostic categories used in this study exhibited a stronger association with seropositivity.¹⁰ These findings suggest a potential association between *B. burgdorferi* infection and psychiatric

morbidity, but fail to identify any specific clinical 'signature' of the infection. This might be due to the very low incidence in an endemic region (0.2%, CI 95% 0.0% to 1.1%) as demonstrated in 517 patients hospitalized for psychiatric diseases.⁹

In addition to serological data, clinical evidence for the association of psychiatric symptoms and post-Lyme disease has also been investigated. If mental and physical complaints in patients were assessed with the von Zerssen's complaint scale using multivariate analyses, the data revealed that definitions of seropositivity were not associated with increased mental or physical complaints.¹¹ In contrast, if the SF-36 was used to determine Quality of Life (QOL) in post-Lyme patients, the average SF-36 physical component summary (40±9, range 29-44) and mental component summary (39±14, range 23-46) of the QOL assessment were worse than the general USA population, and they could be significantly improved by anti-Lyme antibiotics (46% versus 18%, $p=0.007$).⁵ Barr et al.¹² examined the relation between complaints of memory disturbance and measures of mood and memory functioning in 55 patients with serological evidence of late-stage Lyme borreliosis. There was a significant correlation between subjective memory ratings and self-reported depression ($p<0.001$) but not with objective memory performance, indicating memory disturbance in chronic Lyme patients. Using a structured psychiatric interview, the Positive and Negative Affect Schedule, the Lyme Symptom Checklist, and a battery of neuropsychological tests in 30 post-Lyme patients, participants did not appear to have an elevated incidence of psychiatric disorders or psychiatric history.¹³ Their mood, however, was characterized by lowered levels of positive affect and typical levels of negative affect that were similar to affect patterns in individuals with chronic fatigue syndrome (CFS). Similarly, Hassett et al.^{4,7} reported on 240 consecutive post-Lyme patients who were screened for clinical psychiatric disorders, such as depression and anxiety. After adjusting for age and sex, these disorders were more common in symptomatic patients than in the comparison group (Odds Ratio=3.54, CI 95% 1.97-6.55, $p<0.001$), but personality disorders were comparable in both groups.

Although psychiatric co-morbidity and other psychological factors are prominent in post-Lyme patients, it remains uncertain whether these symptoms can be directly attributed to the chronic course of *Borrelia* infections or to other chronic illness-related factors.

Schizophrenia

Several microbes have been suspected as pathogenetic factors in schizophrenia, such as *Chlamydia* species, *Toxoplasma*, and various viruses. For example, a number of studies have reported associations between *Toxoplasma gondii* infection and the risk of schizophrenia with an overall hazard ratio of 1.24.¹⁴ In addition, chlamydial infections have been found in 40% of schizophrenic

patients compared to 7% in healthy controls.¹⁵ These infections represented the highest risk factor yet found to be associated with schizophrenia that was highly significant (Odds Ratio=9.43, $p=1.39 \times 10^{-10}$), especially with *Chlamydia psittaci* (Odds Ratio=24.39, $p=2.81 \times 10^{-7}$). Interestingly, schizophrenic carriers of the HLA-A10 genotype were clearly the most often infected with *Chlamydia*, especially *C. psittaci* (Odds Ratio=50.00, $p=8.03 \times 10^{-5}$), pointing to a genetically related susceptibility.¹⁵ However, skepticism against the role of bacterial infection in schizophrenia was also fostered by the low impact of anti-infectious treatment on the course of disease progression in schizophrenia.¹⁶

Genetic backgrounds and viral infections and/or reactivations as well as cytokine-related pathomechanisms have also been proposed as causative for psychiatric disorders, such as schizophrenia. Specific genetic patterns of MICB polymorphism (MHC class I polypeptide-related sequence B, chromosome 6p21) were identified in patients seropositive for CMV and HSV-1.¹⁷ Similar polymorphisms were found for the COMT Val158Met related to serological evidence of HSV-1 infections in individuals with bipolar disorder.¹⁸ This serologic evidence of HSV-1 infection appeared to be associated with cognitive impairment in individuals with bipolar disorders¹⁹ and was found to be an independent predictor of cognitive dysfunction in individuals with schizophrenia.²⁰ In addition, viral exposure during gestation has been described as a risk factor for schizophrenia. Offspring of mothers with serologic evidence of HSV-2 infection were at significantly increased risk for the development of psychoses (Odds Ratio=1.6; CI 95% 1.1-2.3). These results are consistent with a general model of risk resulting from enhanced maternal immune activation during pregnancy.²¹ However, this was not confirmed in another study.²² Similar contradictory results were observed in a small group of 8 patients with schizophrenia where reactivation of herpesviruses (HSV-1, CMV, EBV, varicella-zoster virus and human HHV-6) and other viruses (measles, rubella, mumps, influenza A and B and Japanese encephalitis viruses) during acute onset or exacerbation of schizophrenia was investigated, but none of these viruses were detected in these patients.²³ Also, a search for HSV-1 or varicella zoster virus infection in postmortem brain tissue from schizophrenic patients did not reveal evidence of persistent CNS infections with these viruses.²⁴

Schizophrenic patients show a number of cytokine changes that may be important in their condition. For example, differences in interleukin-2, -4 and -6, among other cytokines, have been seen in schizophrenic patients.²⁵⁻²⁷ Often these changes in cytokines or cytokine receptors have been linked to associated genetic changes found in schizophrenia.²⁸⁻³⁰ Monji et al.³¹ recently reviewed the evidence for neuroinflammation, increases in pro-inflammatory cytokines and genetic changes in schizophrenia and concluded that these changes are closely linked to activation of microglia. Although the microglia

comprise only about 10% of the total brain cells, they respond rapidly to even minor pathological changes in the brain and may contribute to neurodegeneration through the production of pro-inflammatory cytokines and free radicals. CNS infections could also activate microglia and cause similar events.

Neuropsychiatric Movement Disorders

Gilles de la Tourette's syndrome (TS) is a neurological condition that usually begins in childhood and results in involuntary sounds or words (vocal tics) and body movements (movement tics). An association between infection and TS has been repeatedly described.³² Abrupt onset of the disease, usually after infection, was noted in up to 11% of these patients.³³⁻³⁴ A role for streptococcal infections (PANDAS, see below) as causative or mediating agent in TS was established several years ago.³⁵ Additionally, the involvement of other infectious agents, such as *B. Burgdorferi* or *M. pneumoniae*, has been described in case reports and small studies. For example, comparing 29 TS patients with 29 controls revealed significantly elevated serological titers in TS patients (59% versus 3%). This higher proportion of increased serum titers, especially IgA titers, suggested a putative role for *M. pneumoniae* in a subgroup of patients with TS.³⁶ In predisposed persons, infection with various agents including *M. pneumoniae* should be considered as at least an aggravating factor, but an autoimmune reaction has to be taken into account in TS patients. In addition, co-infections with toxoplasmosis have been described in a few case reports of obsessive-compulsive disorder (OCD).³⁷ As mentioned above, streptococcal infections are likely to play a pivotal role in these syndromes.³⁵

The pathogenic mechanism may be secondary to an activation of the immune system, resulting in an autoimmune response. This will be discussed in the next section.

Autoimmune Diseases

Infections are associated with various autoimmune conditions.³⁸⁻⁴⁰ Autoimmunity can occur when infections like cell-wall-deficient bacteria are released from cells containing parts of cell membranes that are then seen as part of a bacterial antigen complex, or bacteria can synthesize mimicry antigens (glycolipids, glycoproteins or polysaccharides) that are similar enough in structure (molecular mimicry) to stimulate autoimmune responses against similar host antigens. Alternatively, viral infections can weaken or kill cells and thus release cellular antigens, which can stimulate autoimmune responses, or they can incorporate molecules like gangliosides into their structures.

In addition to molecular mimicry, autoimmunity involves several other complex relationships within the host, including inflammatory cytokines, Toll-like receptor signalling, stress or shock proteins, nitric oxide and other stress-related free radicals,

among other changes that together result in autoimmune disease.^{38, 39}

Guillain-Barré syndrome

Guillain-Barré syndrome (GB) is a demyelinating autoimmune neuropathy often associated with bacterial infections.⁴⁰ Symptoms include pain, muscle weakness, numbness or tingling in the arms, legs and face, trouble speaking, chewing and swallowing. Of the types of infections found in GB, *Campylobacter jejuni*, *Mycoplasma pneumoniae* and *Haemophilus influenzae* are often found.³⁹ For example, Taylor et al.⁴¹ found serological evidence of *C. jejuni* in 5 of 7 patients with GB and other motor neuropathies, and Gregson et al.⁴² found anti-ganglioside GM₁ antibodies that cross-reacted with *C. jejuni* liposaccharide isolates. When infections were examined in GB cases in India, Gorthi et al.⁴³ found that 35% and 50% of GB patients had serological evidence of *C. jejuni* and *M. pneumoniae* infections, respectively, while one-third of cases showed evidence of both infections. In Japan Mori et al.⁴⁴ found that 13% of GB patients had antibodies against *Haemophilus influenzae*. Autoantibodies stimulated by infections found in GB patients can cross-react with nerve cell gangliosides (anti-GM₁, anti-GM_{1b}, anti-GD_{1a}, among others), and these are thought to be important in the pathogenesis of GB.⁴⁵ Indeed, injection of *C. jejuni* lipo-oligosaccharide into rabbits induces anti-gangliosides and a neuropathy that resembles acute motor axonal neuropathy.⁴⁶

Viruses have also been found to be associated with GB.⁴⁰ Examples are: CMV,⁴⁷ HIV,⁴⁸ herpes simplex virus,⁴⁹ West Nile virus,⁵⁰ and HHV-6.⁵¹

Paediatric autoimmune neuropsychiatric disorders associated with Streptococci ('PANDAS')

Streptococcal infections in children are usually benign and self-limited. In a small percentage of children, however, prominent neurologic and/or psychiatric sequelae can occur. Post-streptococcal basal ganglia dysfunction has been reported with various manifestations, all of which fall into a relatively well-defined symptom complex or syndrome called paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS).⁵²

Evidence from past studies indicates that adults and children with a symptom course consistent with PANDAS experience subtle neuropsychological deficits similar to those of primary psychiatric diagnosis of OCD and TS.⁵³ PANDAS are now considered as a well-defined syndrome in which tics (motor and/or vocal) and/or OCD are consistently exacerbated in temporal correlation to a group A beta-hemolytic streptococcal infection. However, the pathological relationship between OCD or tics/TS in childhood to antecedent group A *Streptococci* is still not fully understood.⁵²

In an epidemiological investigation Leslie et al.⁵⁴ assessed whether antecedent streptococcal infection(s) increase the risk of subsequent diagnosis of OCD, TS, other tic disorders, attention-deficit hyperactivity disorder (ADHD) or major depressive disorder (MDD). Children with newly diagnosed OCD, TS, or tic disorder were more likely than controls to have had a diagnosis of streptococcal infection in the previous year (Odds Ratio=1.54, CI 95% 1.29-2.15). Previous streptococcal infection was also associated with incident diagnoses of ADHD (Odds Ratio=1.20, CI 95% 1.06-1.35) and MDD (Odds Ratio=1.63, CI 95% 1.12-2.30).⁵⁴ Similar results were found in a retrospective, cross-sectional, observational study of 176 children and adolescents with tics, TS, and related problems.⁵⁵ In a case-control study of children 4 to 13 years old patients with OCD, TS, or tic these disorders were more likely than controls to have had prior streptococcal infection (Odds Ratio=2.22; CI 95% 1.05-4.69) in the 3 months before onset date. The risk was higher among children with multiple streptococcal infections within 12 months (Odds Ratio=3.10; CI 95% 1.77-8.96).⁵⁶ Having multiple infections with *group A beta-hemolytic Streptococcus* within a 12-month period was associated with an increased risk for TS (Odds Ratio=13.6; CI 95% 1.93-51.0). Similar results were found in patients with typical symptoms of Tourette's syndrome.⁵⁷ The frequency of elevated anti-streptolysin O titers was also significantly higher ($p=0.04$) in patients with attention-deficit hyperactivity disorder (64%) than in a control group (34%).⁵⁸

Sydenham's chorea is one manifestation of post-streptococcal neuropsychiatric movement disorders. A pathogenic similarity between Sydenham's chorea, TS and other PANDAS has been suggested since some patients can present with one diagnosis and then evolve with other neuropsychiatric conditions.⁵⁹ These observations support a role of group A streptococcal infection and basal ganglia autoimmunity. Anti-basal ganglia antibodies that are associated with serologic evidence of recent streptococcal infection were found as potential diagnostic markers for this group of disorders, which includes Sydenham's chorea as the prototype.⁶⁰

However, contradictory results were also reported.⁶¹ For example, an association between symptom exacerbations and new *group A beta-hemolytic streptococcus* infections among 47 paediatric patients with TS and/or OCD was not observed.⁵⁹ In addition, the failure of immune markers for streptococcal infections to correlate with clinical exacerbations in a small study of children with paediatric autoimmune neuropsychiatric disorders raised concerns about the viability of autoimmunity as a pathophysiological mechanism in these syndromes.⁶² However, in a second study the same group reported that patients who fit published criteria for paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections represented a subgroup of those with chronic tic disorders and OCD. These patients may be

vulnerable to *group A beta-hemolytic Streptococcus* infection as a precipitant of neuropsychiatric symptom exacerbations.⁶³

Taken together, these findings provide epidemiologic evidence that some paediatric-onset neuropsychiatric disorders, including OCD, tic disorders, ADHD, and MDD, may be, at least partially, related to prior streptococcal infections. *Group A beta-hemolytic Streptococcus* infections are likely not the only event associated with symptom exacerbations for PANDAS patients, but they appear to play a role at least in a subgroup of these children. A potential genetic susceptibility for these post-infectious complexes has been recently proposed.⁶⁴

The recent recognition that these paediatric neurobehavioural syndromes have infectious and/or immunologic triggers has pointed to important new avenues for their management.

Fatiguing illnesses

Chronic fatigue syndrome/myalgic encephalomyelitis

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a fatiguing illness characterised by unexplained, persistent long-term disabling fatigue plus additional signs and symptoms, including neurophysiological symptoms.⁶⁵ Brain imaging studies have shown that CFS/ME patients are dysfunctional in their ventral anterior cingulate cortex, and they also have other brain MRI abnormalities.^{66, 67} In addition, CFS/ME patients also have immunological and inflammation abnormalities, such as alternations in natural killer cell function^{68, 69} and cytokine profiles.^{70, 71} In addition, the hypothalamo-pituitary-adrenal axis, which plays a major role in stress responses, appears to be altered in CFS/ME.⁷²

Most, if not all, CFS/ME patients have multiple chronic bacterial and viral infections.⁷³⁻⁸⁰ For example, when patients were examined for evidence of multiple, systemic bacterial and viral infections, the Odds Ratio for this was found to be 18 (CI 95% 8.5-37.9, $p < 0.001$).⁷⁵ In this study CFS/ME patients had a high prevalence of one of four *Mycoplasma* species (Odds Ratio=13.8, CI 95% 5.8-32.9, $p < 0.001$) and often showed evidence of co-infections with different *Mycoplasma* species, *C. pneumoniae* (Odds Ratio=8.6, CI 95% 1.0-71.1, $p < 0.01$) and HHV-6 (Odds Ratio=4.5, CI 95% 2.0-10.2, $p < 0.001$).⁷⁵ In a separate study the presence of these infections was also related to the number and severity of signs and symptoms in CFS/ME patients, including neurological symptoms.⁷⁷ Similarly, Vojdani et al.⁷⁶ found *Mycoplasma* species in a majority of CFS/ME patients, but this has not been seen in all studies.⁸¹ Interestingly, when European CFS/ME patients were examined for various *Mycoplasma* species, the most common species found was *M. hominis*,⁸² whereas in North America the most common species found was *M. pneumoniae*,^{75, 77} indicating possible regional differences in the types of infections in CFS/ME patients. In addition to *Mycoplasma* species, CFS/ME patients

are also often infected with *B. burgdorferi*,⁸⁰ and as mentioned above, *C. pneumoniae*.^{75, 77, 83}

Other infections are also found in CFS/ME patients, such as viral infections: CMV,⁸⁴ parvovirus B19,⁷⁸ enterovirus⁷⁹ and HHV-6.^{75, 77, 85-88} For example, Ablashi et al.⁸⁸ found that 54% of CFS/ME patients had antibodies against HHV-6 early protein, compared to 8% of controls. Similarly, Patnaik et al.⁸⁶ found that 77% of CFS/ME patients were positive for HHV-6 early antigen IgG or IgM antibodies, whereas only 12% of control subjects had IgG or IgM antibodies to HHV-6 early antigen. Recently a new retrovirus, XMRV, was found in mononuclear blood cells of 67% of 101 chronic fatigue syndrome patients compared to only 3.7% of healthy controls. Cell culture experiments determined that the patient-derived virus was infectious and could possibly be transmitted.⁸⁹

Gulf War illnesses

GWI is a syndrome similar to CFS/ME.⁹⁰ In most GWI patients the variable incubation time, ranging from months to years after presumed exposure, the cyclic nature of the relapsing fevers and the other chronic signs and symptoms, and their subsequent appearance in immediate family members, are consistent with an infectious process.^{90, 91} GWI patients were exposed to a variety of toxic materials including chemicals, radiochemicals and biologicals so not all patients are likely to have infections as their main clinical problem. Neurological symptoms are common in GWI cases.⁹⁰ Baumzweiger and Grove⁹² have described GWI as neuro-immune disorder that involves the central, peripheral and autonomic nervous systems as well as the immune system. They attribute a major source of the illness to brainstem damage and central, peripheral and cranial nerve dysfunction from demyelination. They found GWI patients have muscle spasms, memory and attention deficits, ataxia and increased muscle tone.⁹²

Bacterial infections were a common finding in many GWI patients.⁹⁰ Mycoplasmal infections were found in about one-half of GWI patients, and more than 80% of these cases were PCR positive for *M. fermentans*.^{90, 91, 93-95} In studies of over 1,500 U.S. and British veterans with GWI, approximately 45% of GWI patients have PCR evidence of such infections, compared to 6% in the non-deployed, healthy population. Other infections found in GWI cases at much lower incidence were *Y. pestis*, *Coxiella burnetii* and *Brucella* species.⁹⁰

When we examined the immediate family members of veterans with GWI who became sick only after the veteran returned to the home, we found that >53% had positive tests for mycoplasmal infections and showed symptoms of CFS/ME. Among the CFS/ME-symptomatic family members, most (>80%) had the same *Mycoplasma fermentans* infection as the GWI patients compared to the few non-symptomatic family members who had similar infections (Odds Ratio=16.9, CI 95% 6.0-47.6, $p<0.001$).⁹¹ In contrast, in the few non-

symptomatic family members that tested *Mycoplasma*-positive, the *Mycoplasma* species were often different from the species found in the Gulf War Illness patients (*M. fermentans*). The most sensible conclusion is that veterans came home with *M. fermentans* infections and then transmitted these infections to immediate family members.⁹¹

Some other infectious diseases with neurological aspects

Lyme Disease

Lyme disease is caused by a tick bite and the entry of the spiral-shaped spirochete *B. burgdorferi* as well as other co-infections.⁹⁶ Lyme disease is the most common tick-borne disease in North America. After incubation for a few days to a month, the *Borrelia* spirochete and co-infections migrate through the subcutaneous tissues into the lymph and blood where they can travel to near and distant host sites, including the central nervous system.^{3, 97-99} Transplacental transmission of *B. burgdorferi* and co-infections can occur in pregnant animals, including humans, and blood-borne transmission to humans by blood transfusion is likely but unproven. The tick-borne co-infections associated with Lyme disease can and usually do appear clinically at the same time, complicating clinical diagnoses.¹⁰⁰

Lyme disease signs and symptoms eventually overlap with the signs and symptoms of other chronic illnesses, and patients are often diagnosed with illnesses like CFS/ME, chronic arthritis or a neurological disease.^{80, 97-100} About one-third of cases with Lyme disease start with the appearance of a round, red, bulls-eye skin rash (*erythema migrans*) at the site of the tick bite, usually within 3-30 days.¹⁰⁰ Within days to weeks mild flu-like symptoms can occur that include shaking chills, intermittent fevers and local lymph node swelling. After this localised phase, which can last weeks to months, the infection can spread to other sites resulting in disseminated disease. In the disseminated (late) phase patients present with malaise, fatigue, fever and chills, headaches, stiff neck, facial nerve palsies (Bell's palsy) and muscle and joint pain, and other signs and symptoms.¹⁰⁰⁻¹⁰⁴

The disseminated (late) phase of Lyme disease is a chronic, persistent disease with ophthalmic, cardiac, musculoskeletal, central nervous system and internal organ invasion. When it involves the central and peripheral nervous systems, it is often termed neuroborreliosis.^{100, 104} At this late stage, arthritis, neurological impairment with memory and cognitive loss, cardiac problems (such as myocarditis, endocarditis causing palpitations, pain, bradycardia, hypertension) and severe chronic fatigue are usually apparent.^{80, 100-102} The signs and symptoms of the chronic (late) phase of the disease usually overlap with other chronic conditions, such as CFS/ME, chronic arthritis, as well as neurodegenerative diseases, causing confusion in the diagnosis and treatment of the chronic phase in patients with Lyme Disease.^{80, 97, 100, 105} Patients with late stage neuroborreliosis exhibit neuropathologic and

neuropsychiatric disease similar to some of the neurodegenerative diseases discussed in previous sections.¹

Diagnostic laboratory testing for Lyme disease at various clinical stages is not fool-proof, and experts often use a checklist of signs and symptoms and potential exposures, along with multiple laboratory tests to diagnose Lyme disease.¹⁰⁴ The laboratory tests include serology, Western blot analysis of *B. burgdorferi* associated bands, PCR analysis of blood and the nonspecific decrease in CD-57 natural killer cells. Unfortunately, similar to other intracellular bacteria, *Borrelia* spirochetes are not always released into the blood circulation or other body fluids, making the very sensitive PCR method less than reliable for diagnosing Lyme *Borrelia* with blood samples. Lebech and Hansen¹⁰⁶ found that only 40% of cerebrospinal fluid samples from patients with Lyme neuroborreliosis were positive for *B. burgdorferi* by PCR.

Co-infections in Lyme disease are important but, in general, have not received the attention that *B. burgdorferi* attracts. Some of the Lyme Disease co-infections on their own, such as *M. fermentans*, have been shown to produce signs and symptoms comparable to *B. burgdorferi* infections.^{80, 102}

The most common co-infections found in Lyme disease are species of *Mycoplasma*, mostly *M. fermentans*, present in a majority of cases.^{80, 103, 107} In some cases multiple mycoplasmal infections are present in patients with Lyme disease,⁸⁰ while other common co-infections include *Ehrlichia* species, *Bartonella* species and *Babesia* species. Such co-infections are present in 10-40% of cases.^{103, 104, 108-112} *Ehrlichia* and *Bartonella* species are usually found along with *Mycoplasma* species in Lyme disease.^{94, 98, 108-111} *Bartonella* species, such as *B. henselae*,¹¹¹ which also causes cat-scratch disease,¹¹³ are often found in neurological cases of Lyme disease.^{100, 111}

Protozoan co-infections have been found with *B. burgdorferi*, such as intracellular *Babesia* species.^{100, 108, 109, 112, 114} The combination of *Borrelia*, *Mycoplasma* and *Babesia* infections can be lethal in some patients, and ~7% of patients can have disseminated intravascular coagulation, acute respiratory distress syndrome and heart failure.¹⁰⁹

Brucellosis

Brucellosis is a nonspecific clinical condition characterized by intracellular *Brucella* species infection.¹¹⁵ Approximately 40% of patients with *Brucella* spp. infections have a systemic, multi-organ chronic form of brucellosis that is similar to CFS/ME in its multi-organ signs and symptoms.^{115, 116} *Brucella* infections can invade the central nervous system and cause neurological symptoms.¹¹⁷

Brucella species cause infections in animals, and often humans get the infections from prolonged contact with infected animals. Thus these bacteria are zoonotic, they are capable of

being transmitted from animals to humans. Although there are at least eight species of *Brucella* that are pathogenic, only *B. melitensis*, *B. abortus*, *B. suis* and *B. canis* have been reported to be pathogenic in humans.¹¹⁶

When CFS/ME patients were examined for the presence of *Brucella* spp. infections, approximately 10% showed evidence by PCR of *Brucella* spp. infections (Odds Ratio=8.2, CI 95% 1-66, $p<0.01$).¹¹⁸ Interestingly, urban CFS/ME patients with *Brucella* infections were not as prevalent as rural patients with *Brucella* infections (Odds Ratio=5.5, CI 95% 3-23.5, $p<0.02$), while control subjects had very low (1.4%) rates of infection. Co-infections with *Mycoplasma* species were also found in *Brucella*-positive CFS/ME patients.¹¹⁸

Final comments to part 2

The progression, and in some cases, the inception of many chronic diseases are probably elicited by various bacterial and viral infections.^{1, 39, 40, 119} Even if infections are not directly involved in the pathogenesis of these diseases, patients with chronic conditions are at risk of a variety of opportunistic infections that could result in co-morbid conditions or promote disease progression. Infections can complicate diagnosis and treatment, and patients with late-stage disease with complex neurological manifestations, such as meningitis, encephalitis, peripheral neuropathy, psychiatric conditions, or with other signs and symptoms could have infections that are not recognized or treated.

Patients with chronic diseases are particularly difficult to treat using single modality approaches, and this is particularly true for patients who also have multiple chronic infections.^{103, 109} The multi-focal nature of chronic diseases and the fact that often treatments are given to suppress signs and symptoms, rather than treat causes of the disease or its progression, have resulted in incomplete or ineffective treatments. On the other hand, even if the causes of chronic diseases are known, by the time therapeutic intervention is undertaken, it may be entirely too late to use approaches that should work on the disease if chronic infections were not present. Moreover, if complex, chronic infections are ignored or left untreated, recovery may be difficult, if not impossible to achieve.

At the moment the evidence that particular or specific types of infections are responsible for the inception or pathogenesis of chronic diseases is inconclusive.¹¹⁹ One of the problems that arises in trying to prove this hypothesis is that not all patients appear to have similar chronic infections. Some individuals can harbour chronic infections without any observable signs or symptoms. Although the incidence of chronic infections of the types discussed in this review in symptom-free individuals is generally very low, usually only a few percent,^{74-76, 120} that does not prove that they are important in pathogenesis. Since patients with chronic diseases have been identified that do not have easily diagnosed chronic infections, most researchers have

concluded that infections are not involved in the pathogenesis of chronic diseases. Unfortunately, the tools available to find chronic infections are not optimal, and many patients are likely to go undiagnosed with chronic infections for purely technical reasons.^{1, 119-121}

In the history of medicine animal models of disease have provided useful information that could not be obtained through clinical studies alone. Indeed, the field of chronic diseases could benefit from the greater use of relevant animal models. We suggest that to be useful, the pathogenesis of the animal models of disease must be similar to the pathogenesis of human disease and the animal models must have a similar response to therapy as humans. Thus such models are only relevant if they closely mimic human disease and its response to treatment. For example, the infection of non-human primates with neuropathologic microorganisms, such as *Mycoplasma fermentans*, resulted in brain infections and fatal diseases with clinically typical neurological signs and symptoms.¹²² These primates also respond to therapies that have been used successfully to treat humans.^{93, 123} Thus this particular model may be useful if it can be reproducibly infected with specific microorganisms and later develop neurological signs and symptoms that closely mimic chronic human neurological diseases. Future efforts to determine the relationship between specific infections and the pathogenesis of various chronic diseases may well depend on the further development of relevant animal models.

Competing Interests

None declared

Author Details

GARTH L. NICOLSON, Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, California 92647, USA

JORG HAIER, Department of General and Visceral Surgery, University Hospital, Münster 48149, Germany

CORRESPONDENCE: PROF. GARTH L. NICOLSON, Office of the President, The Institute for Molecular Medicine, P.O. Box 9355, S. Laguna Beach, California, 92652 USA. Website: www.immed.org

Email: gnicolson@immed.org

REFERENCES

1. Nicolson GL, Haier J. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioral, psychiatric, autoimmune and fatiguing illnesses: Part 1. *Br J Med Practit* 2009; 2(4): 20-28.
2. Fallon BA, Nields JA, Parsons B, et al. Psychiatric manifestations of Lyme borreliosis. *J Clin Psychiatry* 1993; 54: 263-268.
3. Fallon BA, Nields JA. Lyme disease: a neuropsychiatric illness. *Am J Psychiatry*. 1994; 151: 1571-1583.
4. Hassett AL, Radvanski DC, Buyske S, et al. Role of psychiatric comorbidity in chronic Lyme disease. *Arthritis Rheum*. 2008; 59: 1742-1749.
5. Cameron D. Severity of Lyme disease with persistent symptoms. Insights from a double-blind placebo-controlled clinical trial. *Minerva Med*. 2008; 99: 489-496.
6. Almeida OP, Lautenschlager NT. Dementia associated with infectious diseases. *Int Psychogeriatr*. 2005; 17(suppl 1): S65-S77.
7. Hassett AL, Radvanski DC, Buyske S, et al. Psychiatric comorbidity and other psychological factors in patients with "chronic Lyme disease". *Am J Med*. 2009; 122: 843-850.

8. Hájek T, Pasková B, Janovská D, et al. Higher prevalence of antibodies to *Borrelia burgdorferi* in psychiatric patients than in healthy subjects. *Am J Psychiatry*. 2002; 159: 297-301.
9. Nadelman RB, Herman E, Wormser GP. Screening for Lyme disease in hospitalized psychiatric patients: prospective serosurvey in an endemic area. *Mt Sinai J Med*. 1997; 64: 409-412.
10. Hájek T, Libiger J, Janovská D, et al. Clinical and demographic characteristics of psychiatric patients seropositive for *Borrelia burgdorferi*. *Eur Psychiatry*. 2006; 21: 118-122.
11. Grabe HJ, Spitzer C, Lüdemann J, et al. No association of seropositivity for anti-*Borrelia* IgG antibody with mental and physical complaints. *Nord J Psychiatry*. 2008; 62: 386-391.
12. Barr WB, Rastogi R, Ravdin L, Hilton E. Relations among indexes of memory disturbance and depression in patients with Lyme borreliosis. *Appl Neuropsychol*. 1999; 6: 12-18.
13. Elkins LE, Pollina DA, Scheffer SR, Krupp LB. Psychological states and neuropsychological performances in chronic Lyme disease. *Appl Neuropsychol*. 1999; 6: 19-26.
14. Niebuhr DW, Millikan AM, Cowan DN, et al. Selected infectious agents and risk of schizophrenia among U.S. military personnel. *Am J Psychiatry*. 2008; 165: 99-106.
15. Fellerhoff B, Laumbacher B, Mueller N, et al. Associations between *Chlamydia* infections, schizophrenia and risk of HLA-A10. *Mol Psychiatry*. 2007; 12: 264-272.
16. Fellerhoff B, Laumbacher B, Wank R. High risk of schizophrenia and other mental disorders associated with chlamydial infections: hypothesis to combine drug treatment and adoptive immunotherapy. *Med Hypotheses*. 2005; 65: 243-252.
17. Loiseleur CR, Wendlandt JT, Rohde CA, Singer HS. Antistreptococcal, neuronal and nuclear antibodies in Tourette syndrome. *Pediatr Neurol*. 2003; 28: 119-125.
18. Dickerson FB, Boronow JJ, Stallings C, et al. The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. *Bipolar Disord*. 2006; 8: 124-132.
19. Dickerson FB, Boronow JJ, Stallings C, et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. *Biol Psychiatry*. 2004; 55: 588-593.
20. Dickerson FB, Boronow JJ, Stallings C, et al. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. *Arch Gen Psychiatry*. 2003; 60: 466-472.
21. Buka SL, Cannon TD, Torrey EF, Yolken RH. Collaborative Study Group on the Perinatal Origins of Severe Psychiatric Disorders. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. *Biol Psychiatry*. 2008; 63: 809-815.
22. Brown AS, Schaefer CA, Quesenberry CP Jr, et al. No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? *Am J Psychiatry*. 2006; 163: 2178-2180.
23. Fukuda R, Sasaki T, Kunugi H, Nanko S. No changes in paired viral antibody titers during the course of acute schizophrenia. *Neuropsychobiology*. 1999; 40: 57-62.
24. Alexander RC, Cabirac G, Lowenkopf T, et al. Search for evidence of herpes simplex virus, type 1, or varicella-zoster virus infection in postmortem brain tissue from schizophrenic patients. *Acta Psychiatr Scand*. 1992; 86: 418-420.
25. Singh B, Bera NK, Nayak CR, Chaudhuri TK. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. *Cytokine*. 2009; 47: 1-5.
26. Schmitt A, Bertsch T, Tost H, et al. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. *Neuropsychiatr Dis Treat*. 2005; 1: 171-177.
27. Watanabe Y, Nunokawa A, Shibuya M, et al. Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population. *Eur Arch Psychiatry Clin Neurosci*. 2008; 258: 422-427.

28. Sun S, Wei J, Li H, et al. A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population. *Brain Res.* 2009; 1268: 13-16.
29. Ozbey U, Tug E, Kara M, Namli M. The value of interleukin-12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. *Psychiatry Clin Neurosci.* 2008; 62: 307-312.
30. Ozbey U, Tug E, Namli M. Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. *World J Biol Psychiatry.* 2009; 19: 1-8 [Epub ahead of print].
31. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. *Psychiatry Clin Neurosci.* 2009; 63: 257-265.
32. Müller N. Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches. *Dialogues Clin Neurosci.* 2007; 9: 161-171.
33. Janik P, Kalbarczyk A, Sitek M. Clinical analysis of Gilles de la Tourette syndrome based on 126 cases. *Neurol Neurochir Pol.* 2007; 41: 381-387.
34. Catarina Prior A, Tavares S, Figueiroa S, et al. Tics in children and adolescents: a retrospective analysis of 78 cases. *An Pediatr (Barc).* 2007; 66: 129-134.
35. Betancourt YM, Jiménez-León JC, Jiménez-Betancourt CS, Castillo VE. Autoimmune neuropsychiatric disorders associated to infection by streptococcus in the paediatric age: PANDAS. *Rev Neurol.* 2003; 36(suppl 1): S95-S107.
36. Müller N, Riedel M, Blendinger C, et al. Mycoplasma pneumoniae infection and Tourette's syndrome. *Psychiatry Res.* 2004; 129: 119-125.
37. Brynska A, Tomaszewicz-Libudzic E, Wolanczyk T. Obsessive-compulsive disorder and acquired toxoplasmosis in two children. *Eur Child Adolesc Psychiatry.* 2001; 10: 200-204.
38. Girschick HJ, Guilherme L, Inman RD, et al. Bacterial triggers and autoimmune rheumatic diseases. *Clin Exptl Rheumatol* 2008; 26: S12-S17.
39. Sherbet G. Bacterial infections and the pathogenesis of autoimmune conditions. *Br J Med Practit* 2009; 2(1): 6-13.
40. Bach JF. Infections and autoimmune diseases. *J Autoimmun* 2005; 25(suppl): 74-80.
41. Talyor BV, Phillips BA, Speed BR, et al. Serological evidence for infection with *Campylobacter jejuni* in patients with multifocal motor neuropathy. *J Clin Neurosci* 1998; 5: 33-35.
42. Gregson NA, Rees JH, Hughes RA. Reactivity of serum anti-GM1 ganglioside antibodies with the lipopolysaccharide fractions of *Campylobacter jejuni* isolates from patients with Guillain-Barre syndrome (GBS). *J Neuroimmunol* 1997; 73: 28-36.
43. Gorthi SP, Kapoor L, Chaudhry R, et al. Guillain-Barré syndrome: association with *Campylobacter jejuni* and *Mycoplasma pneumoniae* infections in India. *Natl Med India* 2006; 19: 137-139.
44. Mori M, Kuwabara S, Miyake M, et al. *Haemophilus influenzae* infection and Gullain-Barré syndrome. *Brain* 2000; 123: 2171-2178.
45. Komagamine T, Yuki N. ganglioside mimicry as a cause of Gullain-Barré syndrome. *CNS Neurol Discord Drug Targets* 2006; 5: 391-400.
46. Hughes RA, Cornblath DR. Gullain-Barré syndrome. *Lancet* 2005; 366: 1653-1666.
47. Igarashi O, Fujioka T, Kishi M, et al. Gullain-Barré syndrome with optic neuritis and cytomegalovirus infection. *J Peripher Nerv Syst* 2005; 10: 340-341.
48. Brannagan TH, Zhou Y. HIV-associated Gullain-Barré syndrome. *J Neurol Sci* 2003; 15: 39-42.
49. Saraf S, Singh RK. GB syndrome with herpes simplex infection. *Indian J Pediatr* 2001; 68: 889-890.
50. Ahmed S, Libman R, Wesson K, et al. Gullain-Barré syndrome: an unusual presentation of West Nile virus infection. *Neurology* 2000; 55: 144-146.
51. Galvan M, Rotola A, Govoni V, et al. Simultaneous Gullain-Barré syndrome and active human herpesvirus 6 infection in the central nervous system. *J Clin Virol* 2007; 38: 271-272.
52. Shulman ST. Pediatric autoimmune neuropsychiatric disorders associated with streptococci (PANDAS): update. *Curr Opin Pediatr.* 2009; 21: 127-130.
53. Hirschtritt ME, Hammond CJ, Luckenbaugh D, et al. Executive and attention functioning among children in the PANDAS subgroup. *Child Neuropsychol.* 2009; 15: 179-194.
54. Leslie DL, Kozma L, Martin A, et al. Neuropsychiatric disorders associated with Streptococcal infection: a case-control study among privately insured children. *J Am Acad Child Adolesc Psychiatry.* 2008; in press.
55. Gabbay V, Coffey BJ, Babb JS, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. *Pediatrics.* 2008; 122: 273-278.
56. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. *Pediatrics.* 2005; 116: 56-60.
57. Müller N, Riedel M, Straube A, et al. Increased anti-streptococcal antibodies in patients with Tourette's syndrome. *Psychiatry Res.* 2000; 94: 43-49.
58. Loiselle CR, Wendlandt JT, Rohde CA, Singer HS. Antistreptococcal, neuronal and nuclear antibodies in Tourette syndrome. *Pediatr Neurol.* 2003; 28: 119-125.
59. Luo F, Leckman JF, Katsoyich L, et al. Prospective longitudinal study of children with tic disorders and/or obsessive-compulsive disorder: relationship of symptom exacerbations to newly acquired streptococcal infections. *Pediatrics.* 2004; 113: e578-e585.
60. Wills A, Dale R, Giovannoni G. Gluten Ataxia and Post-Streptococcal Central Nervous System Syndromes: Emerging Immune-mediated Disorders of the Central Nervous System? *Curr Treat Options Neurol.* 2005; 7: 183-189.
61. Hoekstra PJ, Kallenberg CG, Korf J, Minderaa RB. Is Tourette's syndrome an autoimmune disease? *Mol Psychiatry.* 2002; 7: 437-445.
62. Singer HS, Gause C, Morris C, Lopez P. Tourette Syndrome Study Group. Serial immune markers do not correlate with clinical exacerbations in pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. *Pediatrics.* 2008; 121: 1198-1205.
63. Kurlan R, Johnson D, Kaplan EL, et al. Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. *Pediatrics.* 2008; 121: 1188-1197.
64. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. *Pediatrics.* 2005; 116: 56-60.
65. Fukuda K, Strauss SE, Hickie I, et al. The Chronic Fatigue Syndrome, a comprehensive approach to its definition and study. *Ann Internal Med* 1994; 121: 953-959.
66. de Lange FP, Kalkman JS, Bleijenberg G, et al. Neural correlates of the chronic fatigue syndrome—an fMRI study. *Brain* 2004; 127: 1948-1957.
67. Cook DB, Lange G, DeLuca J et al. Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. *Intern J Neurosci* 2001; 107: 1-6.
68. Fletcher MA, Maher KJ, Klimas NG. Natural Killer cell function in chronic fatigue syndrome. *Clin Appl Immunol Rev* 2002; 2: 129-139.
69. Nijs J, Fremont M. Intercellular immune dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: state of the art and therapeutic implications. *Expert Opin Ther Targets* 2008; 12: 281-289.
70. Skowera A, Cleare A, Blair D, et al. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. *Clin Exp Immunol* 2004; 135: 294-302.
71. Patarca R. Cytokines and chronic fatigue syndrome. *Ann New York Acad Sci* 2001; 933: 185-200.
72. Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. *Stress* 2007; 10: 13-25.
73. Nicolson GL, Nasralla M, Haier J, et al. Mycoplasmal infections in chronic illnesses: Fibromyalgia and Chronic Fatigue Syndromes, Gulf

- War Illness, HIV-AIDS and Rheumatoid Arthritis. *Med Sentinel* 1999; 4: 172-176.
74. Nicolson GL, Haier J, Nasralla M, et al. Mycoplasma infections in Chronic Fatigue Syndrome, Fibromyalgia Syndrome and Gulf War Illness. *J Chronic Fatigue Syndr* 2000; 6(3): 23-39.
 75. Nicolson GL, Nasralla M, Gan R, et al. Evidence for bacterial (Mycoplasma, Chlamydia) and viral (HHV-6) co-infections in chronic fatigue syndrome patients. *J Chronic Fatigue Syndr* 2003; 11(2): 7-20.
 76. Vojdani A, Choppa PC, Tagle C, et al. Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome. *FEMS Immunol Med Microbiol* 1998; 22: 355-365.
 77. Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpesvirus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. *APMIS* 2003; 111: 557-566.
 78. Seishima M, Mizutani Y, Shibuya Y, Arakawa C. Chronic fatigue syndrome after human parvovirus B19 infection without persistent viremia. *Dermatol* 2008; 216: 341-346.
 79. Chia JK, Chia AY. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. *J Clin Pathol* 2008; 61: 43-48.
 80. Nicolson GL, Nicolson NL, Haier J. Chronic Fatigue Syndrome patients subsequently diagnosed with Lyme Disease *Borrelia burgdorferi*: evidence for Mycoplasma species co-infections. *J Chronic Fatigue Syndr* 2008; 15(4): 5-17.
 81. Vernon SD, Shukla SK, Reeves WC. Absence of Mycoplasma species DNA in chronic fatigue syndrome. *J Med Microbiol* 2003; 52: 1027-1028.
 82. Nijs J, Nicolson GL, De Becker P, et al. High prevalence of mycoplasma infections among European Chronic Fatigue Syndrome patients. Examination of four Mycoplasma species in Chronic Fatigue Syndrome patients. *FEMS Immunol Med Microbiol* 2002; 34: 209-214.
 83. Chia JKS, Chia LY. Chronic Chlamydia pneumoniae infection: a treatable cause of Chronic Fatigue Syndrome. *Clin Infect Dis* 1999; 29: 452-453.
 84. Beqaj SH, Lerner AM, Fitzheald JT. Immunossay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome. *J Clin Pathol* 2008; 61: 623-626.
 85. Sairenji T, Yamanishi K, Tachibana Y et al. Antibody responses to Epstein-Bar virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. *Interviol* 1995; 38: 269-273.
 86. Patnaik M, Komaroff AL, Conley C, et al. Prevalence of IgM antibodies to human herpesvirus-6 early antigen in patients with chronic fatigue syndrome. *J Infect Dis* 1995; 172: 1164-1167.
 87. Wagner M, Krueger GRF, Ablashi DV, Whitman JE. Chronic fatigue syndrome (CFS): a critical evaluation of testing for active human herpesvirus-6 (HHV-6) infection: a review of data on 107 cases. *J Chronic Fatigue Syndr* 1996; 5: 3-16.
 88. Ablashi DV, Eastman HB, Owen CB et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. *J Clin Virol* 2000; 16: 179-191.
 89. Lombardi VC, Ruscetti FW, Gupta JD, et al. Detection of a retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. *Science* 2009; online 10.1126/science 1179052.
 90. Nicolson GL, Berns P, Nasralla M et al. Gulf War Illnesses: chemical, radiological and biological exposures resulting in chronic fatiguing illnesses can be identified and treated. *J Chronic Fatigue Syndr* 2003; 11(1): 135-154.
 91. Nicolson GL, Nasralla M, Nicolson NL, et al. High prevalence of mycoplasma infections in symptomatic (Chronic Fatigue Syndrome) family members of mycoplasma-positive Gulf War Illness patients. *J Chronic Fatigue Syndr* 2003; 11(2): 21-36.
 92. Baumzweiger WE, Grove R. Brainstem-Limbic immune dysregulation in 111 Gulf War veterans: a clinical evaluation of its etiology, diagnosis and response to headache treatment. *Intern J Med* 1998; 1: 129-143.
 93. Nicolson GL, Nicolson NL. Diagnosis and treatment of mycoplasma infections in Persian Gulf War Illness-CFIDS patients. *Intern J Occupat Med Immunol Tox* 1996; 5: 69-78.
 94. Nicolson GL, Nicolson NL, Nasralla M. Mycoplasma infections and Chronic Fatigue Illness (Gulf War Illness) associated with deployment to Operation Desert Storm. *Intern J Med* 1998; 1: 80-92.
 95. Vojdani A, Franco AR. Multiplex PCR for the detection of Mycoplasma fermentans, M. hominis and M. penetrans in patients with Chronic Fatigue Syndrome, Fibromyalgia, Rheumatoid Arthritis and Gulf War Illness. *J Chronic Fatigue Syndr* 1999; 5: 187-197.
 96. Burgdorfer WA, Barbour AG, Hayes SF et al. Lyme disease – a tick-borne spirochetosis? *Science* 1982; 216: 1317-1319.
 97. Miklosy J, Khalili K, Gern L, et al. *Borrelia burgdorferi* persists in the brain in chronic Lyme neuroborreliosis and may be associated with Alzheimer's Disease. *J Alzheimer's Dis* 2004; 6: 639-649.
 98. MacDonald AB. Alzheimer's Disease Braak Stage progressions: reexamined and redefined as *Borrelia* infection transmission through neural circuits. *Med Hypotheses* 2007; 68: 1059-1064.
 99. Straubinger RK, Straubinger AF, Harter L, et al. *Borrelia burgdorferi* migrates into joint capsules and causes an upregulation of interleukin-8 in synovial membranes of dogs experimentally infected with ticks, *Infection and Immunity*. 65:1273-1285, 1997.
 100. Gale A, Ringdahl E. Tick-borne diseases. *Am Fam Physician* 2001; 64: 461-466.
 101. Trell J, Grauer MT, Haass A, et al. Chronic fatigue syndrome in patients with Lyme borreliosis. *Eur Neurol* 2000; 43: 107-109.
 102. Coyle PK, Krupp LB, Doscher C, Amin K. *Borrelia burgdorferi* reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic. *Clin Infect Dis* 1994; 18(suppl 1): S24-S27.
 103. Nicolson GL. Diagnosis and therapy of chronic systemic co-infections in Lyme Disease and other tick-borne infectious diseases. *Townsend Lett* 2007; 285: 93-98.
 104. Verdon ME, Sigal LH. Recognition and management of Lyme Disease. *Am Family Physician* 1997; 56: 427-436.
 105. Hansel Y, Ackert M, Stanek G. ALS-like sequelae in chronic neuroborreliosis. *Wien Med Wochensh* 1995; 147: 186-188.
 106. Lebech AM, Hansen K. Detection of *Borrelia burgdorferi* DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction. *J Clin Microbiol* 1992; 30: 1646-1653.
 107. Eskow E, Adelson ME, Rao RV et al. Evidence for disseminated Mycoplasma fermentans in New Jersey residents with antecedent tick attachment and subsequent musculoskeletal symptoms, *J Clin Rheumatol* 2003; 9: 77-87.
 108. Mitchell PD, Reed KD, Hofkes JM. Immunoserologic evidence of coinfection to tick-borne pathogens of babesiosis, ehrlichiosis and Lyme borreliosis in human sera. *J Clin Microbiol* 1996; 34: 724-727.
 109. Burrascano JJ. Diagnostic hints and treatment guidelines for Lyme and other tick-borne diseases. In: *Advanced Topics in Lyme Disease, Managing Lyme Disease*, 16th edition, 5-8, 2008.
 110. Belongia EA, Reed KD, Mitchell PD, et al. Clinical and epidemiological features of early Lyme Disease and human granulocytic ehrlichiosis in Wisconsin. *Clin Infect Dis* 1999; 29: 1472-1477.
 111. E. Eskow E, R.-V. Rao R-V, and E. Mordechai E. Concurrent infection of the central nervous system by *Borrelia burgdorferi* and *Bartonella henselae*. *Arch Neurol* 2001; 58: 1357-1363.
 112. Mylonakis E. When to suspect and how to monitor Babesiosis. *Am Fam Physician* 2001; 63: 1969-1974.
 113. Armengol CE, Hendley JD. Cat-scratch disease encephalopathy: a cause of status epilepticus in school-aged children. *J Pediatr* 1999; 134: 635-638.
 114. Krause PJ, Telford SR III, Spielman A, et al. Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness. *JAMA* 1996; 275: 1657-1660.

115. Corbel MJ. Brucellosis: an overview. *Emerg Infect Dis* 1997;3: 313-321.
 116. Young EJ. An overview of human brucellosis. *Clin Infect Dis* 1995; 21: 283-290.
 117. McLean DR, N. Russell N, Khan Y. Neurobrucellosis: clinical and therapeutic features. *Clin Infect Dis* 1992; 15: 582-590.
 118. Nicolson GL, Gan R, and Haier J. Evidence for Brucella species and Mycoplasma species co-Infections in blood of Chronic Fatigue Syndrome patients. *J Chronic Fatigue Syndr* 2005; 12(2): 5-17.
 119. Nicolson GL. Chronic infections in neurodegenerative and neurobehavioral diseases. *Lab Med* 2008; 39(5): 291-299.
 120. Nicolson GL, Gan R, Nicolson NL, Haier J. Evidence for Mycoplasma, Chlamydia pneumoniae and HHV-6 co-infections in the blood of patients with Autism Spectrum Disorders. *J Neurosci Res* 2007; 85: 1143-1148.
 121. Greenlee JE, Rose JW. Controversies in neurological infectious diseases. *Semin Neurol* 2000; 20: 375-386. *J Neurosci Res* 2007; 85: 1143-1148.
 122. Lo SC, Wear DJ, Shih WK, et al. Fatal systemic infections of non-human primates by Mycoplasma fermentans (incognitus strain). *Clin Infect Dis* 1993;17(suppl 1): S283-S288.
 123. Lo S-C, Buchholz CL, Wear DJ, et al. Histopathology and doxycycline treatment in a previously healthy non-AIDS patient systemically infected by Mycoplasma fermentans (incognitus strain). *Mod Pathol* 1991; 6: 750-754.
-